Retatrutide
TRIUMPH-1
Eli Lilly · Phase 3 · Completed · Enrollment 2335
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| retatrutide 4 mg | n/r | n/r | n/r | n/r |
| retatrutide 9 mg | n/r | n/r | n/r | n/r |
| retatrutide 12 mg | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- retatrutide 4 mg: endpoint not reported
- retatrutide 9 mg: endpoint not reported
- retatrutide 12 mg: endpoint not reported
- Placebo: endpoint not reported